Mary-Elizabeth Percival

Trials

Studies that name Mary-Elizabeth Percival as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03737955 · Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

  University of Washington · recruiting · Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT02756572 · Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

  University of Washington · completed · Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm · principal investigator
• N/A
  NCT02551718 · High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

  University of Washington · completed · Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer Center Administration
  P30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026
  Named on NCT02756572, NCT02551718